1. Home
  2. PNTG vs LYEL Comparison

PNTG vs LYEL Comparison

Compare PNTG & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Pennant Group Inc.

PNTG

The Pennant Group Inc.

N/A

Current Price

$40.46

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$10.96

Market Cap

320.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PNTG
LYEL
Founded
2019
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
320.1M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
PNTG
LYEL
Price
$40.46
$10.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$37.00
$30.60
AVG Volume (30 Days)
201.0K
98.2K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
N/A
EPS
0.49
N/A
Revenue
$947,705,000.00
$36,000.00
Revenue This Year
$24.72
N/A
Revenue Next Year
$7.61
$8,712.13
P/E Ratio
$81.57
N/A
Revenue Growth
36.31
N/A
52 Week Low
$22.26
$11.47
52 Week High
$42.69
$45.00

Technical Indicators

Market Signals
Indicator
PNTG
LYEL
Relative Strength Index (RSI) 58.89 28.91
Support Level $38.50 N/A
Resistance Level $40.55 $15.38
Average True Range (ATR) 1.20 0.84
MACD 0.24 -0.44
Stochastic Oscillator 91.34 7.41

Price Performance

Historical Comparison
PNTG
LYEL

About PNTG The Pennant Group Inc.

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: